- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Asthma and chronic obstructive pulmonary disease (COPD)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 535KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 109KB)
Fluticasone propionate + salmeterol – November 2023
Fluticasone Propionate + Salmeterol: Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses, Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses; Salflumix® Easyhaler®
Last updated
1 March 2024
